Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses
According to the data of a phase II clinical trial reported at the 2011 World Congress on Osteoarthritis, nano-formulations of diclofenac offer better pain relief at lower-than-normal doses.
The diclofenac trial is part of Iroko Pharmaceuticals’ multi-drug development program to utilize proprietary nanotechnology for the reformulation of a wide class of pain relief drugs called non-steroidal anti-inflammatory drugs (NSAIDs). Nano-formulations decrease the size of drug particles which in turn improve their dissolution in the body.
The multi-drug development program intends to utilize Iroko Pharmaceuticals’ proprietary SoluMatrix technology to reduce the dosages of NSAIDs and systemic exposure by 20% in order to enhance their tolerance and protection, while sustaining their efficiency. Standard Diclofenac formulations are NSAIDs that have been utilized as pain relievers for diseases such as osteoarthritis.
The standard dosages of diclofenac are 25 and 50 mg but the dosages of its nano-formulations presented at the Congress were 18 and 35 mg when compared to placebo. A significant finding was overall pain relief as informed at intervals more than 12 h (TOTPAR-12) by patients who suffered from severe dental pain due to third-molar removal. The study also showed statistically significant difference for nano-formulations in terms of improvement in pain relief. When compared with the pain reliever celecoxib with a dose of 400 mg, the nano-formulations demonstrated numerically better scores by TOTPAR-12 estimation.
The nano-formulations also demonstrated that they are statistically superior to placebo and numerically superior to celecoxib for TOTPAR assessment for 4 and 8 h. More findings of the Phase II clinical trials of nano-formulated NSAIDs being developed by Iroko will be reported at another important medical conference in 2011.
Please use one of the following formats to cite this article in your essay, paper or report:
APA
Chai, Cameron. (2019, February 12). Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses. AZoNano. Retrieved on March 18, 2026 from https://www.azonano.com/news.aspx?newsID=23406.
MLA
Chai, Cameron. "Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses". AZoNano. 18 March 2026. <https://www.azonano.com/news.aspx?newsID=23406>.
Chicago
Chai, Cameron. "Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses". AZoNano. https://www.azonano.com/news.aspx?newsID=23406. (accessed March 18, 2026).
Harvard
Chai, Cameron. 2019. Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses. AZoNano, viewed 18 March 2026, https://www.azonano.com/news.aspx?newsID=23406.
We're committed to providing free access to quality science. By registering and providing insight into
your preferences you're joining a community of over 1m science interested individuals and help us to
provide you with insightful content whilst keeping our service free.
or
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.